OpenURL Connection Search

Select item for more details and to access through your institution.

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Published in:
2022
By:
- Jerusalem, Guy;
- Delea, Thomas E.;
- Martin, Migule;
- Laurentiis, Michelino De;
- Nusch, Arnd;
- Beck, J. Thaddeus;
- Arlene Chan;
- Seock-Ah Im;
- Neven, Patrick;
- Lonshteyn, Alexander;
- Chandiwana, David;
- Lanoue, Brad;
- Fasching, Peter A.;
- De Laurentiis, Michelino;
- Chan, Arlene;
- Im, Seock-Ah
Publication type:
journal article
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221081203
By:
- Tripathy, Debu;
- Curteis, Tristan;
- Hurvitz, Sara;
- Yardley, Denise;
- Franke, Fabio;
- Babu, K. Govind;
- Wheatley-Price, Paul;
- Im, Young-Hyuck;
- Pencheva, Radost;
- Eddowes, Lucy A.;
- Dionne, Pierre-Alexandre;
- Chandiwana, David;
- Pathak, Purnima;
- Lanoue, Brad;
- Harbeck, Nadia
Publication type:
Article
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).
Published in:
Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920943065
By:
- Harbeck, Nadia;
- Franke, Fabio;
- Villanueva-Vazquez, Rafael;
- Lu, Yen-Shen;
- Tripathy, Debu;
- Chow, Louis;
- Babu, Govind K;
- Im, Young-Hyuck;
- Chandiwana, David;
- Gaur, Anil;
- Lanoue, Brad;
- Rodriguez-Lorenc, Karen;
- Bardia, Aditya
Publication type:
Article
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer.
Published in:
Cancer Management & Research, 2021, v. 13, p. 8179, doi. 10.2147/CMAR.S325043
By:
- Fasching, Peter A;
- Delea, Thomas E;
- Lu, Yen-Shen;
- De Boer, Richard;
- Hurvitz, Sara A;
- Moynahan, Aaron;
- Chandiwana, David;
- Lanoue, Brad;
- Hu, Huilin;
- Thuerigen, Astrid;
- O'Shaughnessy, Joyce
Publication type:
Article

Found: 4

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.

Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer.

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7).

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer.